Amphastar Pharmaceuticals Future Growth
Future criteria checks 3/6
Amphastar Pharmaceuticals is forecast to grow earnings and revenue by 14.9% and 10.3% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be 26.5% in 3 years.
Key information
14.9%
Earnings growth rate
13.7%
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | 10.3% |
| Future return on equity | 26.5% |
| Analyst coverage | Good |
| Last updated | 23 Oct 2024 |
Recent future growth updates
Recent updates
Amphastar: Objectively Undervalued But For Good Reason (Rating Downgrade)
Oct 25Investors Continue Waiting On Sidelines For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)
Sep 15
Amphastar: Perplexing Pipeline, Lumpy Revenues - I'm On Sidelines
Sep 12Is Amphastar Pharmaceuticals (NASDAQ:AMPH) Using Too Much Debt?
Aug 27Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 05Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Jul 01Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Subdued P/E Might Signal An Opportunity
May 30Amphastar Pharmaceuticals: Buy When Fear Is Overblown
May 30Reassessing Amphastar Pharmaceuticals
May 15Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Pretty Healthy Balance Sheet
Mar 27Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
Mar 04Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Might Deserve Your Attention Today
Jan 04Why Investors Shouldn't Be Surprised By Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) P/E
Dec 20Amphastar Pharmaceuticals (NASDAQ:AMPH) Has A Rock Solid Balance Sheet
Dec 03Amphastar Pharmaceuticals (NASDAQ:AMPH) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18An Intrinsic Calculation For Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Suggests It's 35% Undervalued
Sep 03These 4 Measures Indicate That Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Using Debt Safely
Aug 17Here's Why We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Is Well Worth Watching
Jun 02We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
May 11Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Intrinsic Value Is Potentially 51% Above Its Share Price
Mar 02Is Now The Time To Put Amphastar Pharmaceuticals (NASDAQ:AMPH) On Your Watchlist?
Feb 07Does Amphastar Pharmaceuticals (NASDAQ:AMPH) Have A Healthy Balance Sheet?
Jan 24Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Nov 02Amphastar: A Pharmaceutical Growth Stock
Oct 06Amphastar wins FDA approval for Epinephrine pre-filled syringes
Aug 16Amphastar Pharmaceuticals: Compelling Growth Prospects For H2 2022 And Beyond
Aug 08Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Jul 24Amphastar generic vasopressin for increasing blood pressure gets FDA approval
Jul 19We Think Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt With Ease
Jun 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 912 | 253 | 240 | 308 | 4 |
| 12/31/2025 | 819 | 221 | 214 | 262 | 5 |
| 12/31/2024 | 747 | 204 | 168 | 221 | 6 |
| 6/30/2024 | 713 | 167 | 178 | 213 | N/A |
| 3/31/2024 | 676 | 155 | 161 | 198 | N/A |
| 12/31/2023 | 644 | 138 | 145 | 184 | N/A |
| 9/30/2023 | 601 | 135 | 140 | 175 | N/A |
| 6/30/2023 | 541 | 102 | 100 | 131 | N/A |
| 3/31/2023 | 519 | 93 | 51 | 79 | N/A |
| 12/31/2022 | 499 | 91 | 65 | 89 | N/A |
| 9/30/2022 | 485 | 77 | 90 | 114 | N/A |
| 6/30/2022 | 477 | 91 | 70 | 97 | N/A |
| 3/31/2022 | 455 | 81 | 100 | 126 | N/A |
| 12/31/2021 | 438 | 62 | 71 | 98 | N/A |
| 9/30/2021 | 413 | 36 | 45 | 74 | N/A |
| 6/30/2021 | 384 | 10 | 52 | 81 | N/A |
| 3/31/2021 | 368 | 2 | 45 | 79 | N/A |
| 12/31/2020 | 350 | 1 | 23 | 57 | N/A |
| 9/30/2020 | 337 | 7 | 13 | 46 | N/A |
| 6/30/2020 | 334 | 4 | -11 | 25 | N/A |
| 3/31/2020 | 327 | 52 | 12 | 47 | N/A |
| 12/31/2019 | 322 | 49 | 0 | 42 | N/A |
| 9/30/2019 | 329 | 52 | 3 | 46 | N/A |
| 6/30/2019 | 324 | 53 | 27 | 73 | N/A |
| 3/31/2019 | 316 | 2 | -23 | 26 | N/A |
| 12/31/2018 | 295 | -6 | -4 | 38 | N/A |
| 9/30/2018 | 265 | -7 | -5 | 38 | N/A |
| 6/30/2018 | 248 | -9 | -15 | 25 | N/A |
| 3/31/2018 | 242 | -4 | N/A | 25 | N/A |
| 12/31/2017 | 240 | 4 | N/A | 39 | N/A |
| 9/30/2017 | 243 | 0 | N/A | 43 | N/A |
| 6/30/2017 | 250 | 4 | N/A | 42 | N/A |
| 3/31/2017 | 252 | 9 | N/A | 47 | N/A |
| 12/31/2016 | 255 | 10 | N/A | 39 | N/A |
| 9/30/2016 | 269 | 21 | N/A | 28 | N/A |
| 6/30/2016 | 268 | 14 | N/A | 30 | N/A |
| 3/31/2016 | 254 | 0 | N/A | 23 | N/A |
| 12/31/2015 | 252 | -3 | N/A | 11 | N/A |
| 9/30/2015 | 230 | -13 | N/A | 20 | N/A |
| 6/30/2015 | 226 | -15 | N/A | 30 | N/A |
| 3/31/2015 | 221 | -10 | N/A | 28 | N/A |
| 12/31/2014 | 210 | -11 | N/A | 21 | N/A |
| 9/30/2014 | 209 | -6 | N/A | 17 | N/A |
| 6/30/2014 | 209 | -1 | N/A | 4 | N/A |
| 3/31/2014 | 223 | 8 | N/A | 24 | N/A |
| 12/31/2013 | 230 | 12 | N/A | 31 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMPH's forecast earnings growth (14.9% per year) is above the savings rate (2.5%).
Earnings vs Market: AMPH's earnings (14.9% per year) are forecast to grow slower than the US market (15.2% per year).
High Growth Earnings: AMPH's earnings are forecast to grow, but not significantly.
Revenue vs Market: AMPH's revenue (10.3% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: AMPH's revenue (10.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AMPH's Return on Equity is forecast to be high in 3 years time (26.5%)